Related references
Note: Only part of the references are listed.Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3
Justin K. Murray et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Blocking KV1.3 Channels Inhibits Th2 Lymphocyte Function and Treats a Rat Model of Asthma
Shyny Koshy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Targeting the Ion Channel Kv1.3 with Scorpion Venom Peptides Engineered for Potency, Selectivity, and Half-life
Wilson Edwards et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Engineering a Potent and Specific Blocker of Voltage-Gated Potassium Channel Kv1.3, a Target for Autoimmune Diseases
Rong Chen et al.
BIOCHEMISTRY (2012)
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases
Victor Chi et al.
TOXICON (2012)
Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease
Eric J. Tarcha et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Modeling the Binding of Three Toxins to the Voltage-Gated Potassium Channel (Kv1.3)
Rong Chen et al.
BIOPHYSICAL JOURNAL (2011)
Regulation of NF-κB induction by TCR/CD28
Jing Cheng et al.
IMMUNOLOGIC RESEARCH (2011)
The Beneficial Effect of Blocking Kv1.3 in the Psoriasiform SCID Mouse Model
Amos Gilhar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells
Keishi Adachi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
CTLA4-Ig inhibits allergic airway inflammation by a novel CD28-independent, nitric oxide synthase-dependent mechanism
Christine M. Deppong et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis
Toshitake Hyodo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
The functional network of ion channels in T lymphocytes
Michael D. Cahalan et al.
IMMUNOLOGICAL REVIEWS (2009)
KCNE4 suppresses Kv1.3 currents by modulating trafficking, surface expression and channel gating
Laura Sole et al.
JOURNAL OF CELL SCIENCE (2009)
Engineering a Stable and Selective Peptide Blocker of the Kv1.3 Channel in T Lymphocytes
M. W. Pennington et al.
MOLECULAR PHARMACOLOGY (2009)
Voltage-gated potassium channels as therapeutic targets
Heike Wulff et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Blockade of T-Lymphocyte KCa3.1 and Kv1.3 Channels as Novel Immunosuppression Strategy to Prevent Kidney Allograft Rejection
I. Grgic et al.
TRANSPLANTATION PROCEEDINGS (2009)
Inhibitor of sarco-endoplasmic reticulum Ca2+-ATPase thapsigargin stimulates production of nitric oxide and secretion of interferon-gamma
Eva Kmonickova et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Imaging of Effector Memory T Cells during a Delayed-Type Hypersensitivity Reaction and Suppression by Kv1.3 Channel Block
Melanie P. Matheu et al.
IMMUNITY (2008)
Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes
Yunzhao R. Ren et al.
PLOS ONE (2008)
Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes
Ildiko Szabo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
OdK2, a Kv1.3 channel-selective toxin from the venom of the Iranian scorpion Odonthobuthus doriae
Yousra Abdel-Mottaleb et al.
TOXICON (2008)
The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation
Christine Beeton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
From T-cell activation signals to signaling control of anti-cancer immunity
Shane J. F. Cronin et al.
IMMUNOLOGICAL REVIEWS (2007)
Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes
Lina Hu et al.
JOURNAL OF IMMUNOLOGY (2007)
Signalling to transcription:: Store-operated Ca2+ entry and NFAT activation in lymphocytes
Yousang Gwack et al.
CELL CALCIUM (2007)
Altered dynamics of kv1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus
Stella A. Nicolaou et al.
JOURNAL OF IMMUNOLOGY (2007)
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis
Philippe Azam et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Biochemical and functional characterization of Orai proteins
Yousang Gwack et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Christine Beeton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases
A Schmitz et al.
MOLECULAR PHARMACOLOGY (2005)
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases
C Beeton et al.
MOLECULAR PHARMACOLOGY (2005)
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom
S Mouhat et al.
BIOCHEMICAL JOURNAL (2005)
Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2
C Zitt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells
G Panyi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: A possible role in T cell proliferation
L Conforti et al.
JOURNAL OF IMMUNOLOGY (2003)
Direct observation of ligand recognition by T cells
DJ Irvine et al.
NATURE (2002)
Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation
C Beeton et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
